Literature DB >> 2173704

Synthetic peptide analogs of DARPP-32 (Mr 32,000 dopamine- and cAMP-regulated phosphoprotein), an inhibitor of protein phosphatase-1. Phosphorylation, dephosphorylation, and inhibitory activity.

H C Hemmings1, A C Nairn, J I Elliott, P Greengard.   

Abstract

Synthetic peptides based on the threonine phosphorylation site and proposed inhibitory site of DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, Mr = 32,000 as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis) were prepared and analyzed as substrates for cAMP-dependent protein kinase and protein phosphatases-1c, -2Ac (the catalytic subunits of protein phosphatase-1 and 2A, respectively) and -2B, and as inhibitors of protein phosphatase-1c. Studies of the kinetics of phosphorylation of the peptides by cAMP-dependent protein kinase indicated an important role in facilitating phosphorylation for the region COOH-terminal to the phosphorylatable threonyl residue. Studies of the dephosphorylation of the phosphopeptides demonstrated that they were effectively dephosphorylated by protein phosphatase-2A and -2B and poorly dephosphorylated by protein phosphatase-1. The active inhibitory region of phospho-DARPP-32 was analyzed by determining the effects of synthetic phosphopeptides on the activity of protein phosphatase-1c. Phospho-D32-(8-48) and phospho-D32-(8-38) inhibited protein phosphatase-1c with IC50 values of 2 x 10(-8) and 4 x 10(-8) M, respectively, compared with an IC50 of 8 x 10(-9) M for intact phospho-DARPP-32. Phospho-D32-(9-38) was equipotent with phospho-D32-(8-38); however, further NH2-terminal deletions resulted in marked reductions in IC50 values. An analog of an active DARPP-32 phosphopeptide containing a phosphoseryl residue in place of the phosphothreonyl residue also exhibited a much reduced IC50. These data identify the essential inhibitory region of phospho-DARPP-32 as residues 9-38, which contains the phosphorylation site (Thr34). This region exhibits extensive amino acid sequence identity with phosphatase inhibitor-1, a distinct inhibitor of protein phosphatase-1. Kinetic studies of the inhibition of protein phosphatase-1c by phospho-D32-(9-38), a potent inhibitor, as well as by phospho-D32-(10-38), a weak inhibitor, indicated a mixed competitive/noncompetitive mechanism of inhibition, as has been previously found for both intact phospho-DARPP-32 and intact phospho-inhibitor-1. These findings support the hypothesis that a 30-amino acid domain in the NH2-terminal region of phospho-DARPP-32 is sufficient for the inhibition of protein phosphatase-1.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2173704

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Molecular identification of human G-substrate, a possible downstream component of the cGMP-dependent protein kinase cascade in cerebellar Purkinje cells.

Authors:  S Endo; M Suzuki; M Sumi; A C Nairn; R Morita; K Yamakawa; P Greengard; M Ito
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

2.  The dopamine and cAMP regulated phosphoprotein, 32 kDa (DARPP-32) signaling pathway: a novel therapeutic target in traumatic brain injury.

Authors:  James W Bales; Hong Q Yan; Xiecheng Ma; Youming Li; Ranmal Samarasinghe; C Edward Dixon
Journal:  Exp Neurol       Date:  2011-03-01       Impact factor: 5.330

3.  Prenatal exposure to cocaine disrupts D1A dopamine receptor function via selective inhibition of protein phosphatase 1 pathway in rabbit frontal cortex.

Authors:  X Zhen; C Torres; H Y Wang; E Friedman
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

4.  Site-directed mutagenesis of amino acid residues of protein phosphatase 1 involved in catalysis and inhibitor binding.

Authors:  H B Huang; A Horiuchi; J Goldberg; P Greengard; A C Nairn
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

5.  Characterization of the interaction between DARPP-32 and protein phosphatase 1 (PP-1): DARPP-32 peptides antagonize the interaction of PP-1 with binding proteins.

Authors:  Y G Kwon; H B Huang; F Desdouits; J A Girault; P Greengard; A C Nairn
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

6.  GBPI, a novel gastrointestinal- and brain-specific PP1-inhibitory protein, is activated by PKC and inactivated by PKA.

Authors:  Qing-Rong Liu; Ping-Wu Zhang; Zhicheng Lin; Qi-Fu Li; Amina S Woods; Juan Troncoso; George R Uhl
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

7.  The protein phosphatases of Synechocystis sp. strain PCC 6803: open reading frames sll1033 and sll1387 encode enzymes that exhibit both protein-serine and protein-tyrosine phosphatase activity in vitro.

Authors:  Renhui Li; M Ben Potters; Liang Shi; Peter J Kennelly
Journal:  J Bacteriol       Date:  2005-09       Impact factor: 3.490

8.  Detailed structural characterization of unbound protein phosphatase 1 inhibitors.

Authors:  Barbara Dancheck; Angus C Nairn; Wolfgang Peti
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

9.  Phosphorylated Mr 32,000 dopamine- and cAMP-regulated phosphoprotein inhibits Na+,K(+)-ATPase activity in renal tubule cells.

Authors:  A Aperia; J Fryckstedt; L Svensson; H C Hemmings; A C Nairn; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

10.  Mechanism of regulation of casein kinase I activity by group I metabotropic glutamate receptors.

Authors:  Feng Liu; David M Virshup; Angus C Nairn; Paul Greengard
Journal:  J Biol Chem       Date:  2002-09-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.